Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Geron Corp 919 EAST HILLSDALE BOULEVARD SUITE 250 FOSTER CITY CA 94404 USA

www.geron.com Employees: 141 P: 650-473-7700 F: 650-473-7750

Description:

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Key Statistics

Overview:

Market Capitalization, $K 2,477,492
Enterprise Value, $K 2,488,292
Shares Outstanding, K 602,796
Annual Sales, $ 240 K
Annual Net Income, $ -184,130 K
Last Quarter Sales, $ 880 K
Last Quarter Net Income, $ -67,380 K
EBIT, $ -227,360 K
EBITDA, $ -236,390 K
60-Month Beta 0.52
% of Insider Shareholders 3.10%
% of Institutional Shareholders 73.71%
Float, K 584,109
% Float 96.90%
Short Volume Ratio 0.50

Growth:

1-Year Return 114.65%
3-Year Return 149.09%
5-Year Return 177.70%
5-Year Revenue Growth -77.57%
5-Year Earnings Growth -100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 08/08/24
Next Earnings Date 11/07/24 [BMO]
Earnings Per Share ttm -0.36
EPS Growth vs. Prev Qtr -11.11%
EPS Growth vs. Prev Year -11.11%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GERN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -73.79%
Return-on-Assets % -50.51%
Profit Margin % -76,720.84%
Debt/Equity 0.27
Price/Sales 10,453.55
Price/Cash Flow N/A
Price/Book 7.95
Book Value/Share 0.52
Interest Coverage -21.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar